{"id":"NCT00442338","sponsor":"Organon and Co","briefTitle":"Study of MK-0476 in Adult Patients With Acute Asthma (0476-334)","officialTitle":"MK-476 IV Formulation Phase III Open Label Exploratory Comparative Study - Acute Exacerbations of Asthma -","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-03","primaryCompletion":"2007-08","completion":"2007-08","firstPosted":"2007-03-01","resultsPosted":"2009-07-14","lastUpdate":"2022-02-02"},"enrollment":91,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"montelukast sodium","otherNames":["MK-0476"]},{"type":"DRUG","name":"montelukast sodium","otherNames":["MK-0476"]},{"type":"DRUG","name":"aminophylline hydrate","otherNames":["KyophyllinÂ® Injection 2.5%, FK05"]}],"arms":[{"label":"Montelukast 7 mg","type":"EXPERIMENTAL"},{"label":"Montelukast 14 mg","type":"EXPERIMENTAL"},{"label":"Aminophylline 250 mg","type":"ACTIVE_COMPARATOR"}],"summary":"The study estimates the efficacy and safety of MK0476 and aminophylline intravenous administration in adult participants with acute asthma.","primaryOutcome":{"measure":"Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Within the First 60 Minutes After Administration","timeFrame":"Baseline and 60 minutes after study drug administration","effectByArm":[{"arm":"Montelukast 7 mg","deltaMin":0.07,"sd":null},{"arm":"Montelukast 14 mg","deltaMin":0.05,"sd":null},{"arm":"Aminophylline 250 mg","deltaMin":0.06,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.871"},{"comp":"OG001 vs OG002","p":"0.794"},{"comp":"OG000 vs OG001","p":"0.675"}]},"eligibility":{"minAge":"15 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":30},"commonTop":["Glucose urine present","Diarrhea","Oedema","White blood cell count increased"]}}